Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Lapatinib in High-Risk SCCHN
NCT00424255Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2006
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Lapatinib+Chemoradiation with Placebo+Chemoradiation (2 arms). Primary endpoint: Disease Free Survival at 101 weeks. Started Dec 2006; status: completed.
02
Drugs
lapatinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00424255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424255.